REZOLUTE, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
REZOLUTE, INC. (RZLT) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price of $4.86 per share for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-24.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-09-24
- REZOLUTE, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2025-09-30 was $4.61.
- REZOLUTE, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2023-09-30 was $12.67.
- REZOLUTE, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2026 was $4.86, a 60.07% decline from fiscal 2025.
- REZOLUTE, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2025 was $12.17, a 99.18% increase from fiscal 2024.
- REZOLUTE, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2024 was $6.11, a 85.00% decline from fiscal 2023.
- REZOLUTE, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2023 was $40.73, a 114.03% increase from fiscal 2022.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.86 10-K · filed 2026-09-24 | |||
| 2026-03-31 | $4.85 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $26.84 10-Q · filed 2026-02-12 | |||
| 2025-09-30 | $4.61 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $12.17 10-K · filed 2026-09-24 | |||
| 2025-03-31 | $14.39 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | $12.28 10-Q · filed 2025-02-12 | |||
| 2024-06-30 | $6.11 10-K · filed 2025-09-17 | |||
| 2024-03-31 | $9.49 10-Q · filed 2024-05-15 | |||
| 2023-12-31 | $9.49 10-Q · filed 2024-02-13 | |||
| 2023-09-30 | $12.67 10-Q · filed 2023-11-13 | |||
| 2023-06-30 | $40.73 10-K · filed 2024-09-19 | |||
| 2023-03-31 | $40.73 10-Q · filed 2023-05-11 | |||
| 2022-06-30 | $19.03 10-K · filed 2023-09-14 | |||
| 2022-03-31 | $20.19 10-Q · filed 2022-05-12 | |||
| 2021-06-30 | $50.29 10-K · filed 2022-09-15 | |||
| 2018-06-30 | $4.50 10-K · filed 2019-09-10 | |||
| 2018-03-31 | $4.50 10-Q · filed 2018-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |